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Abstract
Biomedical imaging techniques can provide a vast amount of anatomical information, enabling 
diagnosis and the monitoring of disease and treatment profile. MRI uniquely offers convenient, 
non-invasive, high resolution tomographic imaging. A considerable amount of effort has been 
invested, across several decades, in the design of non toxic paramagnetic contrast agents capable 
of enhancing positive MRI signal contrast. Recently, focus has shifted towards the development of 
agents capable of specifically reporting on their local biochemical environment, where a switch in 
image contrast is triggered by a specific stimulus/biochemical variable. Such an ability would not 
only strengthen diagnosis but also provide unique disease-specific biochemical insight. This 
feature article focuses on recent progress in the development of MRI contrast switching with 
molecular, macromolecular and nanoparticle-based agents.
1. Introduction
There exist a wide variety of spatially resolved clinical imaging modalities, including 
positron emission tomography (PET), computed tomography (CT), ultrasound, optical 
imaging and magnetic resonance imaging (MRI).1 Of these, MRI stands out through its 
combination of convenient non-invasive application, high spatial resolution, and 
tomographic capability. This modality can provide images of the anatomy and physiology of 
living subjects by rapidly mapping out the spatial distribution of the proton (1H) signal 
intensity. Originally termed nuclear magnetic resonance imaging upon its discovery in the 
1940s (renamed MRI in the 1970s due to deemed negative connotations associated with the 
term ‘nuclear’), this imaging technique works by exploiting the phenomenon of nuclear 
magnetic resonance (NMR) and, specifically, the reaction to a strong external magnetic field 
(B0) of magnetic atomic nuclei, which absorb and re-emit electromagnetic waves at a 
characteristic radio frequency (RF). In a static magnetic field, nuclei process at a (Larmor) 
frequency (ω0), which is linearly dependent on B0 and the gyromagnetic ratio of the nucleus 
γ, according to eqn (1).
(1)
The application of a RF pulse causes the net magnetisation vector associated with these 
processing and thermally equilibrated nuclei to flip from a position parallel to the external 
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field to one transverse. The process of their relaxation back to the equilibrium state can 
occur by two different mechanisms, namely those which are longitudinal (or spin–lattice, 
T1) or transverse (or spin–spin, T2) in nature. An MR imaging system exploits the current 
generated by the motion of these relaxing magnetic moments by constructing a time domain 
NMR signal and using a Fourier transform to generate a frequency domain spectrum from 
which relaxation times may be derived. Images can be generated from these signals in 
different ways, most commonly by monitoring nuclear relaxation after a series of spaced RF 
pulses, which can then be spatially resolved electronically. Subsequently acquired image 
contrast in anatomical models is generated, in the first instance, from variance in water 
content across different body tissues. The inherently low sensitivity of MRI (arising 
primarily from the small energetic differential associated with nuclear Zeeman splitting) 
generally requires that this contrast be boosted through the use of added contrast agents, if it 
is to be diagnostically useful. Contrast agents work to enhance MR contrast by locally 
reducing T1 and T2 relaxation times.2-5 Those that predominantly reduce T1 are referred to 
as “positive” contrast agents and result in increases in signal intensity (bright contrast), 
whereas those which primarily affect T2 are commonly known as “negative”, providing 
reductions in signal intensity (dark contrast). Clinically, T1 agents offer higher spatial 
resolution and are not associated with false signal reading due to the existence of other 
signal draining sources in tissues that can plague T2 modalities. The most common T1 
contrast agents currently used are paramagnetic gadolinium ion complexes (Gd3+), due to 
their seven unpaired electrons, large magnetic moment and long electronic relaxation time 
(9–10 s), which contribute to enhanced relaxation according to the parameters set out in the 
Solomon, Bloembergen and Morgan (SBM) theory (vide infra).6,7 Free Gd3+, however, is 
toxic, disrupting physiological Ca2+ signalling;8,9 kinetically robust chelation of Gd3+ with 
ligands such as tetraazacyclododecane-tetraacetic acid (DOTA) is, thus, commonly 
employed.10,11 Such agents make up the majority of those in current clinical use, including 
gadopentetate dimeglumine (Magnevist), gadoterate meglumine (Dotarem), gadoteridol 
(ProHance) and gadodiamide (Omniscan).12,13 This article will focus on progress made in 
further engineering such Gd binding scaffolds so as to engender high image contrast with 
additional responsiveness to chemical or biological stimuli of physiological relevance.
2. Molecular contrast agents (CAs)
In order to enhance image contrast obtained from molecular T1 agents (such as those listed 
above), optimisation of the parameters that govern relaxivity have been investigated in detail 
for several decades, most commonly with concurrent reference to the SBM theory.3,14,15 
Indeed, relaxivity (r1), defined by eqn (2), describing the change in relaxation rate (Δ(1/T1) 
= ΔR1) of water protons in the presence of a specified concentration of contrast agent 
([CA]), is dependent on external field, temperature, the electronic properties of the 
paramagnetic centre, water residence time (τm), rotational correlation time (τR), first and 
second coordination sphere hydration (q), and the ion to water proton distance.3 In general, 
enhanced relaxivity can be achieved by increasing the q value, shortening τm and increasing 
τR.
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(2)
T1 relaxation originates, in part, from dipolar interactions between the imaged water protons 
and local paramagnetic species. The former may be inner-sphere (IS, those directly 
coordinated to the Gd3+ centre), second-sphere (SS, those hydrating the complex) or outer-
sphere (OS, those diffusing near the chelate, governed by translational diffusion, τD), as 
depicted in Fig. 1, with their relaxation rates contributing to the overall relaxation rate 
according to eqn (3).
Inner-sphere contributions are thought to be the most important in the relaxation of 
molecular paramagnetic species (eqn (4), where T1m is the longitudinal water proton 
relaxation time)16 and have hence dominated investigations where chelating ligand structure 
has been tuned to facilitate relaxation enhancement,3,6 or, more recently, report on 
immediate microenvironment.3,17,18
(3)
(4)
2.1 Responsive molecular contrast agents
In living organisms, variations in tissue and cellular microenvironment can provide vital 
information about the status of healthy or diseased tissues, organs and tumours. A specific 
sensitivity of MR image contrast to a physiological or biochemical reaction in tissue is the 
main focus of the emerging discipline of functional MRI.19 The most well-known example 
of this is blood-oxygen-level-dependent (BOLD) contrast, which depicts differences in 
blood oxygenation related to neural activity.20 This technique provides MR contrast change 
through the imaging of haemoglobin (Hb) and the extreme sensitivity of this to oxygenation 
(an accompanying transformation of Hb from paramagnetic to diamagnetic).
The most common method of facilitating an MRI contrast response to environment with 
lanthanide macrocycles is through variations in hydration state (q value), often facilitated by 
conformation change.16,21 The second-sphere water molecule dynamics of a chelate can also 
be manipulated by an environmental trigger, providing variation in MRI signal contrast.22-25 
Responsive conformation changes can alternatively result in a change in contrast agent 
molecular volume, affecting τR and hence T1m.26 Increases in the molecular weight of a 
contrast agent, through cross-linking or polymerisation, can also be prompted by an 
environmental stimulus, resulting in image contrast enhancement through the reduction of 
molecular tumbling rates (increasing τR). It is worth noting here that, in the design of agents 
for conventional MRI, permanent enhancement of signal contrast is the desired goal; in 
functional MRI, specific change in response to a physiological trigger (and the degree and 
specificity of relaxivity change) is more important than the absolute magnitude.
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2.2 Bio-responsive molecular contrast agents
Potentially the most important developing class of responsive MRI is that based on agents 
that are acted on by pathologically relevant enzymes such as those associated with disease 
states including stroke, cerebral ischemia, cardiovascular or neurodegenerative 
inflammatory processes.27 Pioneering work by Meade and co-workers in the late 1990s, for 
example, paved the way towards the development of responsive or ‘smart’ MRI contrast 
agents specifically designed to respond to an enzymatic cleavage.28 Their work describes a 
family of 4,7,10-tri(acetic acid)-1-(2-β-galactopyranosylethoxy)-1,4,7,10-tetraazacyclo-
dodecane gadolinium (EGad) contrast agents, whose galactopyranose groups are removed 
by β-galactosidase (an important reporter marker for monitoring gene expression), resulting 
in an irreversible transition from a weak to a strong relaxivity state. A 20% change in 
relaxation rate is observed through the removal of a H2O blocking group, increasing q and, 
thus, improving inner sphere T1 relaxation (Fig. 2). Since then, several similar approaches 
have been published describing the modulation of MRI contrast through the control of water 
access to a chelated paramagnetic centre.29-31 These have achieved 3-fold increases in 
relaxation rate upon enzymatic cleavage of the hydration-hindering group.29 An alternative 
approach has been offered by Giardiello et al., who prepared a neutral complex that binds 
with high affinity to H2O-blocking HCO3− anions and displays low relaxivity. The action of 
a specific enzyme (porcine liver esterase) on the modified side arms of this DOTA 
derivative introduces new anionic charge, repels the chelating HCO3− ions increases metal 
hydration, and triggers a ~90% increase in signal contrast.32 Reliance on inner sphere 
hydration as the mechanism of MRI contrast modulation, however, is not ideal. Anion 
interactions with the cleaved (more solvated/accessible) paramagnetic species, has, in 
particular, been identified to be a considerable interfering factor, particularly in vivo, where 
water-competing anions are abundant.30 Such interactions can have a significant detrimental 
effect on resulting relaxivity and any assumptions therein; alternative mechanisms to 
achieve MRI activation have, therefore, been investigated.
One such mechanism is the so-called receptor-induced magnetisation effect (RIME), which 
utilises binding of a target moiety, such as a protein, to a paramagnetic chelate, resulting in 
the formation of a bulky, slow-tumbling macromolecular contrast agent with increased τR 
(and thus relaxation/contrast relative to background; Fig. 3).33 In this vein, Breckwoldt et al. 
have employed a bis-5-hydroxytryptamide-diethylenetriamine-pentatacetate gadolinium 
species, which, in the presence of the enzyme myeloperoxidase (MPO, a key enzyme 
secreted in the inflammatory response to tissue injury), oxidises and radicalises, leading to 
cross-linking, polymerisation and subsequent protein binding.27 Successful triggering of 
relaxation enhancement was non-invasively monitored in vivo, allowing tracking of MPO 
activity in stroke-affected mice models. A Gd3+-diethylenetriaminepentaacetic acid (DTPA) 
type construct with a phosphonate side-chain, termed MS-325 by Caravan et al., which 
targets human serum albumin (HSA), again employs the RIME strategy to provide selective 
vascular MRI enhancement. In this case, HSA binding limits extravasation of the free 
chelate from the blood pool into the non-vascular space, slowing renal excretion and 
contributing to an extended blood half-life and also thus providing vascular-specific 
relaxation rate enhancement. A 9-fold increase in relaxivity (at 20 MHz) was observed upon 
non-covalent HSA binding in ex situ studies, due to slowing molecular rotation (τR) of the 
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HSA-bound MS-325 entity.33 A similar strategy employs a Gd3+-chelate functionalised with 
a trilysine masking group with associated poor native HSA affinity (and hence low 
relaxivity, r1 = 9.8 mM−1 s−1 at 20 MHz, 37 °C). Upon cleavage of the lysine residues by 
human carboxy peptidase B, a thrombin-activatable fibrinolysis inhibitor (TAFI, an 
important enzyme in thrombotic disease), the chelate–HSA affinity increases substantially 
due to the exposure of aryl groups with high HSA binding affinity, a transition with an 
associated 170% relaxivity enhancement (to 26.5 mM−1 s−1 at 20 MHz, 37 °C).34 Sherry 
and co-workers have designed a Gd–DO3A-peptide-based CA that is τR activated upon 
binding to a specific target protein in a similar vein.35 The relaxivity of this CA (r1 = 8.3 ± 
0.2 mM−1 s−1 at 20 MHz) increases substantially upon addition of the target protein and 
phantom T1-weighted imaging demonstrates a 10-fold improvement in image intensity for 
the chelate in the presence of the binding protein. More recently, Gd3+–DO3A ligands 
bearing a pendant diphenylphosphinamide arm have been shown to possess a high affinity 
for HSA, boosting r1 by 54–119% due to increases in τR.36 The degree of relaxivity 
switching, however, was adversely affected by the displacement of inner sphere water 
molecules by carboxylate residues of the protein, an inherent problem often observed in the 
presence of oxygen-based chelates.
The vast array of diagnostically potent functional enzymes and proteins present 
physiologically makes this class of bioresponsive CAs arguably the most important in 
detecting and monitoring disease pathology. The examples of bio-responsive switchable 
CAs referred to herein represent some of the most effective (in terms of the degree of 
switching) of this class so far available and exploit robust change in q or τR. It should be 
highlighted, however, that the majority of these cases present irreversible changes in 
contrast, with a ‘one-off’ trigger facilitating the contrast enhancement or reduction. Further 
work will be required to generate derived CAs capable of long-term use or disease treatment 
profiling.
2.3 Cation responsive molecular contrast agents
Another important class of biologically activatable CAs are those which can be triggered by 
the presence of metal ions. Metal ions are vital in a variety of physiological pathways. Ca2+ 
ions for example, play an important role in neural signalling and changes in brain activity 
can lead to variations in its concentration. Similarly, increased Zn2+ ion concentrations have 
been implicated in environments commonly associated with Alzheimer’s disease.37 Cation 
responsive contrast would therefore undoubtedly be diagnostically potent.38 In the design of 
such, signal changes are once again most commonly effected through variance in hydration 
number of paramagnetic CA complexes. There have been several examples exploiting this in 
recent literature, most of which employ conformation changes and associated perturbations 
in inner-sphere water access and q. The first reports of a Zn2+-specific CA reporter were by 
Hanaoka et al., who described DTPA–bisamide chelators which respond sensitively and 
selectively to Zn2+ through the displacement of inner sphere water arising from a Zn2+ 
binding induced geometrical reconfiguration.39,40 Such systems observed a ~33% decrease 
in relaxivity due to the inhibition of water access to the Gd3+-chelator upon cation binding. 
Gadolinium complexes with bis-15-crown-5 ether or β-diketone recognition sites have also 
been prepared to enable the detection of K+, Mg2+ or Ca2+ ions, with MRI signal contrast 
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again decreasing due to a geometrical rearrangement in the presence of the metal ion, and 
associated change in the second sphere of paramagnet hydration.41 Within this study, the 
most efficient MRI response was observed for β-diketone tethered Gd–DTPA species, 
whose r1 relaxivity (4.98 mM−1 s−1 at 20 MHz) decreased 20.7% (to 3.95 mM−1 s−1) in the 
presence of Mg2+ ions.
These modulations, based on decreases or ‘turning-off’ of image contrast, are less desirable 
than systems which result in image brightening through specifically triggered relaxivity 
increase. Groups such as that of De Leon-Rodriguez and co-workers have prepared Gd3+–
DOTA chelates appended with N,N-bis-(2-pyridylmethyl) ethylene diamine (bisBPEN) 
diamide functionalities which are capable of binding Zn2+. Such species successfully exhibit 
a modest ion-specific increase in r1 relaxivity of 20% (from 5 to 6 mM−1 s−1 at 23 MHz) 
with the introduction of 2 equivalents of Zn2+ ions (with similar changes observed in the 
presence of Cu2+ ions).42 These changes were attributed to an increase in water exchange 
rate upon ion binding, or alternatively, the creation of a more organised second sphere of 
water molecules (bound to the Zn2+ or Cu2+ ions) in close proximity to the single Gd3+-
bound water molecules of the complex. This group has recently improved upon this by using 
a Gd–DOTA derivative containing two bis-(3-pyrazolyl) units, yielding a 64% relaxivity 
enhancement with introduction of Zn2+ ions, also demonstrating successful in vivo 
application.43 Interestingly, these groups also describe significant further r1 relaxation 
enhancement of the Zn2+-coordinated complex upon binding to human serum albumin 
(HSA), providing a 165% increase (from 6.6 to 17.4 mM−1 s−1), a rotational correlation time 
(τR) effect only occurring in the presence of the metal ions.42 Major et al. have 
demonstrated that the design of the chelate species can play a vitally important role in 
relaxivity modulation by specific cations.44,45 Their asymmetric chelates display an acetate 
pendant arm capable of switching its coordination to either the paramagnetic centre of the 
contrast agent or a cation, such as Zn2+. Coordination to the former centre generates a 
coordinatively saturated chelate, with q = 0 and hence low MRI contrast. Coordination to a 
Zn2+ ion causes a change in the molecular geometry and the Gd3+ coordination sphere, 
leading to an increase in hydration number to q = 1 (Fig. 4), and 121% increase in r1 
relaxivity (from r1 = 2.3 to 5.1 mM−1 s−1 at 60 MHz). Subsequent in vitro studies 
demonstrated a qualitative increase in T1-weighted image contrast of the agent in the 
presence of physiologically relevant concentrations of Zn2+.44
Specificity amongst metal ions can, of course, be an important factor for consideration in the 
design of metal ion-modulating MRI contrast. Gd-chelates have been designed to recognise 
various different metal ions, including Cu2+, Ca2+, Mg2+ and K+ with selectivities generally 
utilising Irving-Williams governed trends in affinity as well as coordination environment 
preferences.46 Ethylene glycol tetraacetic acid (EGTA, a highly selective Ca2+ chelator) has, 
for example, been bound to two macrocyclic Gd3+-containing moieties, with Ca2+ ion 
binding causing increases in the inner-sphere hydration number of the chelate and 
concomitant modest associated protic longitudinal relaxivity increases (32% from r1 = 5.4 to 
7.1 mM−1 s−1 at 500 MHz).46 Similar constructs exploiting q to effect a contrast change 
have shown 83% increases in relaxivity in the presence of Ca2+ (from r1 = 3.4 to 6.3 mM−1 
s−1 at 500 MHz); at physiological concentrations, such as those in the relevant range for 
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Ca2+ modulation in the brain (0.8–1.2 mM), relaxivity changes of ~10% are observed.47 
Similarly, DOPTA–Gd complexes structurally modulate inner-sphere water access to the 
chelated Gd3+ ion using iminoacetate arms, which shield the paramagnetic centres from 
water in the absence of Ca2+ ions (q = 0).48 Upon binding of Ca2+, the complex undergoes a 
reorganisation leading to an increase in q and relaxivity by 80% to 5.8 mM−1 s−1 (at 500 
MHz) over Ca2+ concentrations ranging 0.1–10 μM. Cu+/Cu2+ ion selectivity has been 
achieved by Que et al. through the design of Gd–DO3A chelates coupled to acetate or 
thioether-rich receptor ligands, which rely upon modest q modulation through Cu2+ binding 
(eliciting a 40% change in relaxivity).49,50 Similarly, Pope and co-workers use a bis-
macrocylic ligand which recognises Hg2+ to generate a 24% increase in relaxivity.51 The 
highest increase in longitudinal MRI relaxation exploiting a hydration change mechanism 
has been observed for thioether-tethered DO3A chelates, demonstrating a 360% increase in 
r1 upon binding 1 equivalent of Cu2+ (from 1.5 to 6.9 mM−1 s−1 at 20 MHz).50 The initially 
low r1 observed in the absence of metal ions in this work is suggestive of a q = 0, with the 
acetate or pyridine moieties present on the linker initially capping inner-sphere water access 
(a cap that is removed on the association of Cu2+ ions; Fig. 5). A polyarginine modified 
version of this chelate has demonstrated some promise in initial intracellular work.52 
Recently, several others have reported a variety of Gd–DOTA-based chelates with pendant 
arms capable of cation binding, providing relaxivity responses due to q modulation.53-55
Modulation of MRI contrast based on metal ion recognition by a CA can also be achieved 
through exploitation of rotational correlation time. Peters and co-workers have investigated 
bisphosphonate appended coordination oligomers of a DOTA-like chelator as a means of 
generating cation triggered changes in rotational correlation time.56 This resulted in 200–
500% increases in r1 (depending on Zn2+ concentration), although it was noted that 
selectivity would be poor under physiological conditions. A 250% relaxivity enhancement 
of Gd–DOTA–diBPEN in response to Zn2+ ions has recently been translated reasonably 
well to both ex vivo and in vivo studies, an effect which relies upon binding of the Zn2+-
bound-chelate species to HSA and resulting changes in τR.57 Several groups have 
investigated heterometallic complexes featuring Gd-chelates which self-assemble to form 
bulky macromolecules upon coordination to iron ions.58-61 Comblin et al., for example, 
have designed a Gd(phen)HDO3A chelate (r1 = 3.7 mM−1 s−1 at 20 MHz) which uses its 
phenanthroline-like unit to complex Fe2+ ions, forming a tris-complex with very high 
molecular weight, with an associated relaxivity increase to 12.2 mM−1 s−1.11 Toth and co-
workers have developed a metallostar structure comprising six densely packed Gd3+–
diethylenetriaminetetraacetic acid (DTTA) chelates around an Fe2+ ion, resulting in an 
almost 2-fold increase in relaxivity (from 12.4 to 20.2 mM−1 s−1 at 20 MHz).59 The 
formation of slowly rotating macromolecular species with increased τR is responsible for the 
observed enhancements throughout all these works. An alternative method for metal ion 
detection employing relaxivity responses which has been explored by Muller et al. describes 
the transmetallation of a DTPA-derived chelate (MS-325) which releases Gd3+ into solution 
in the presence of Zn2+ ions, resulting in insoluble Gd–phosphate complexes which 
precipitate and hence no longer contribute to the observed 1H r1 relaxivity.62 This process 
leads to a 25% reduction in r1 after 5000 min. The timescale and associated toxicity risk of 
this method, however, is unlikely to make it practically relevant.
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There have been, then, a number of reported approaches to tune r1 relaxation through 
association with physiologically relevant levels of cations. In nearly all cases this has been 
through the modulation of water access or rotational correlation time and accompanied by 
varying degrees of relaxivity switching (20–360%). Bar some obvious exceptions, 
performance is both modest and detrimentally affected in attempts to extrapolate to 
physiological in vivo conditions. Though much work clearly remains to be done, particularly 
in safeguarding specificity, these prior reports show promise and are likely to underpin 
future developments.
2.4 pH-responsive molecular contrast agents
MRI contrast agents capable of detecting variations in environmental pH can be of particular 
use for the non-invasive detection of disease or metabolic disorder.63 Ischemia, for example, 
is often defined by low pH (caused by amide exchange due to regional neural ischemia, for 
instance) and can characterise heart disease. Similarly, regions of acidity can indicate the 
presence of hypoxia, tumour growth and metastases (malignant tumours present with pHs 
ranging from 6.8–7.2).64 pH reporters can hence provide important information which can 
impact directly upon selected treatment (e.g. hypoxic tumour cells are resistant to radiation 
and to many anticancer drugs65) and a monitoring of their efficacy. It is unsurprising then 
that a range of paramagnetic agents have been developed in which hydration state, leading to 
either increases or decreases in signal, is highly pH dependent.
Pagliarin and co-workers have, for example, described a series of Ln3+ macrocyclic 
complexes in which the presence of a β-arylsulfonamide group on the chelate species 
supports pH dependent relaxivity (as well as luminescence).16 These systems are based on 
protonation of the sulphonamide nitrogen and the associated increase from q = 0 to q = 1 
(with a 48% increase in r1 relaxivity values over the pH range 7.4–6.8 and concomitant 
decrease in photoluminescent emissivity due to water based quenching). Hall et al. have 
synthesised terpyridine-based Gd3+-chelates which demonstrate decreasing relaxivities with 
increasing pH (from r1 = 12.8 mM−1 s−1 at pH 6 to r1 = 2 mM−1 s−1 at pH 11, at 20 MHz), 
attributed to an overall decrease in q from 3 to 0, due to the successive deprotonation of 
water molecules and subsequent formation of dimeric complexes possessing no bound water 
molecules.66
An alternative approach to pH modulation of MRI is to exploit proton exchange between 
inner sphere coordinated water molecules and bulk water due to highly acidic/basic 
environments. This approach has been employed by Aime et al., who have described a range 
of C4-symmetric Gd3+–DOTA-type chelates with different pendent arms demonstrating 
largely invariant relaxivity between pH 2–8 (where r1 ≈ 2.5 mM−1 s−1 at 20 MHz, due to 
only outer-sphere contributions), but marked increases in r1 at very high (>10; r1 ≈ 5.7 
mM−1 s−1 at 20 MHz) and very low (<2; r1 ≈ 5 mM−1 s−1 at 20 MHz) pH 
environments.22,23 The observed increases in relaxation behaviour at these two extremes are 
attributed to the formation of a well-defined second hydration sphere, where water 
molecules are in rapid exchange. In strongly basic media this is ascribed to deprotonation of 
bound water molecules or proximate ligand amide NH protons. In acidic media these 
beneficial changes are ascribed to protic-catalysed dissociation of the ion-paired water–Gd-
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complexes, promoting water exchange. Similar work by Sherry and co-workers has 
described Gd3+–DOTA complexes with phosphonate pendent arms with strong pH-
dependent r1 behaviour, demonstrating two relaxivity troughs, the first having a 40% 
variation between pH 2–6 and 70% between pH 6–12, with an r1 maximum at pH 6, 
observations again ascribed to protic exchange between bound water protons and bulk 
solvent protons contributing to a second hydration sphere possessing rapidly exchanging 
water molecules.24,25
A major limitation inherent in the field of responsive contrast lies in the lack of ability to 
quantify the concentration of contrast agent present at the site of interest (meaning, in turn, 
that relaxivities resulting from any trigger can only be qualitative). There is, then, much 
interest in the development of ratiometric responsive CAs and most development thus far 
has been associated with those which respond to local pH. Sherry and co-workers have, for 
example, investigated such a system (employing a mixture of pH-insensitive GdDOTP5− 
and pH sensitive GdDOTA-4AmP5− chelates with necessary assumptions about identical 
biodistribution) and demonstrated its efficacy both in vitro and in vivo.17,67 An alternative 
approach is to measure the ratio between the transverse and longitudinal paramagnetic 
relaxation rates of water protons in response to a single contrast agent (R2/R1), as described 
by Terreno and co-workers.68 This approach, based on a Gd3+-complex having τm or 
rotational mobility dependent on pH, allows an assessment which is independent of contrast 
agent concentration. Bimodal agents employing a second imaging technique using a dual-
functional probe can also provide quantification of local contrast agent concentration and 
hence relaxivity,69 an approach adopted in work by Frullano et al., which saw the 
production of a dual MRI-PET agent composed of the pH-dependent GdDOTA-4AMP 
chelate appended with a18/19F functionality.70 A linear relationship between the PET and 
MRI signals allowed determination of the concentration of the agent through comparison 
with a pH calibration curve, providing a quantitatively accurate non-invasive probe of great 
promise for in vivo application.
To summarise thus far, the most common and controllable approach to effect relaxation 
change by pH modulation is through exploitation of the hydration state (q) of molecular 
contrast agents. In this way, enhancement or reduction of signal contrast can be attained, 
with modest (up to 70%) changes over relevant physiological pH ranges (pH 6–8).24 The 
use of protic exchange and second hydration sphere dynamics can provide an alternative pH 
responsive route to MRI contrast modulation, although the most significant responses occur 
at very high (>10) or very low (<2) pH regions, making such responses less physiologically 
relevant. To allow unambiguous assessment of MRI contrast modulation, the contrast agent 
concentration must be accurately known, a particularly difficult prospect in site-targeting 
and in vivo applications. Responsive ratiometric contrast agents offer great potential in this 
area and some initial investigations have demonstrated promise.
2.5 Redox responsive molecular contrast agents
Redox reactions are widespread in biochemical systems, with organisms integrating them 
directly within fundamental methods of energy generation. A change in oxidising/reducing 
condition can result from variations in blood flow, oxygenation and other variables and can 
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have a profound effect on physiological function, such as those in the brain accompanying 
stroke, Parkinson’s and Alzheimer’s diseases.71 Very often such physiological stress is 
associated with increased reactive oxygen species (ROS) and decreased antioxidant 
levels.72,73 One can seek to directly acquire tomographic mapping of such conditions 
through the use of paramagnetic agents which are, in some capacity, redox active.
One non-metallic class of such are the nitroxides, which undergo reduction to diamagnetic 
hydroxylamines, resulting in a marked and reversible contrast change.71,73 These aside, T1-
weighted contrast agents demonstrating redox triggered contrast switching are rare.74-76 
Louie and co-workers have described the only Gd3+-based T1-contrast agents capable of 
redox sensing using a Gd3+–DOTA system featuring a spiropyran/merocyanine motif, 
demonstrating 26% relaxivity decreases upon redox activation (from 2.5 to 1.9 mM−1 s−1 at 
60 MHz), caused by decreasing hydration number (from q = 1.16 to 0.44) as a result of a 
conformation change.74,75 An 8-coordinate chelate complex tethered with acyclic 
merocyanine converts to its spirocyclic isomer, a 7-coordinate chelate, following reduction 
using nicotinamide adenine dinucleotide (NADH). This structural change increases the 
hydration number of the complex (from q = 1 to q = 2), resulting in a 54% increase in 
relaxivity; a change which is reversible upon treatment with hydrogen peroxide (Fig. 6).74
A slightly different mechanistic approach has also been explored towards the development 
of redox switchable CAs sensitive to environmental O2 partial pressure (pO2, which is 
relevant in various pathological diseases, including stroke and tumours), exploiting 
variations in the chelate metal centre oxidation state, similar to the BOLD method of 
activated detection earlier described.77 In this vein, Terreno and co-workers have 
investigated manganese (Mn2+/3+) porphyrin complexes which were encapsulated into 
cyclodextrin (CD) hosts.78 Oxidation of Mn2+ complexes to Mn3+ by O2 was associated 
with ~50% decreases in MR signal intensity (r1 = 5 mM−1 s−1 to 2.5 mM−1 s−1 at 20 MHz); 
changes attributed to a combination of electron spin density delocalisation and changes in 
the number of labile protons at the metal centre.78-80 This system allows quantification of 
pO2 (0–40 Torr) in the region of interest. Some Eu2+ analogues have also been investigated 
as potential redox-responsive probes, due to their isoelectronic relationship with Gd3+. Burai 
et al., for example, have investigated chelates based on cryptates, which, although not 
experimentally verified, have potential for strong redox triggered MRI contrast switching 
capabilities upon oxidation of Eu2+ to Eu3+.77,81
Though there exist, then, a number of elegant examples of redox responsive MR contrast 
which have been applied in vitro, it is clear that much more work needs to be done before 
the realisation of reliable and marked switching of signal contrast in vivo.
2.6 Light responsive molecular contrast agents
Bioluminescence imaging is a useful non-invasive modality providing potentially excellent 
signal-to-noise, spatial refinement and high throughput. Although poor tissue penetration 
makes it a less tractable means of switching contrast than other methods noted thus far, light 
emitting gene markers, such as those based on lucerase–luciferin could potentially provide 
an appropriate application for photoactivatable agents.21,82 To this end, a small number of 
articles have hence described the development of light-sensitive MRI contrast agents based 
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on spirobenzopyrans, which undergo an isomeric conformation change upon light 
irradiation, affecting water coordination (q) at the paramagnetic metal centre.21,75 This 
transformation (which is reversible) prevents hydration at the metal centre, resulting in a 
reduction in relaxivity of about 21% (from r1 = 3.7 mM−1 s−1 to 2.9 mM−1 s−1 at 60 
MHz).75 Though modest, this work may find application if, for example, larger relaxivity 
changes can be married with NiR wavelength triggering.
3. Macromolecular and nanoparticle contrast agents
Small molecule CAs have paved the way for enhanced medical imaging (including that 
which is targeted and/or multimodal), and facilitated most of what we understand in terms of 
tuning CA behaviour in vitro and in vivo. However, their limitations, in particular rapid 
elimination, and the quest for signal amplification, have resulted in the increased utilisation 
of higher molecular weight species offering inherently striking and, in many cases, 
profoundly advantageous characteristics.13
Relaxivity can be improved by the incorporation of paramagnetic gadolinium centres 
directly into a nanosized matrix to obtain, for example, GdF3:CeF3 nanoaggregates coated 
with poly(acrylic acid) chains,83 doped zeolite GdNaY,84 gadofullerenes,85 
gadonanotubes,86 GdF3:citrate,87 or PEG–phosphate coated NaGdF4 nanoparticles.88 
Though a number of these derivations are associated with high MR contrast, they very often 
exhibit low kinetic stability and hence potentially high levels of toxicity. A preferred method 
of increasing signal contrast is by embedding or conjugating numerous clinically approved 
Gd3+-chelates to macromolecules or nanoparticulates based on polymers,89 dendrimers,90 
liposomes,91 micelles,92 proteins,93 virus capsids,94 gold glyconanoparticles,95 or silica.96 
These approaches primarily exploit the inherently large particle surface area and size to 
improve MRI signal. Before looking at some of the characteristics associated with the 
paramagnetic modification of such species, we briefly review the mechanisms associated 
with the dipole–dipole longitudinal relaxation mechanism. As outlined earlier (eqn (3) and 
(4)), inner-sphere contributions generally dominate relaxation enhancement. The 
longitudinal relaxation rate of the bound water (1/T1m) is given by eqn (5). These 
expressions confirm that the relaxation behaviour of a complex depends on a number of 
parameters, including the distance between the unpaired electron spin of Gd3+ and protons 
of the coordinated H2O (rGdh), the angular proton Larmor frequency (ωI) and the global and 
local correlation times (τCG and τCL, respectively, defined by eqn (6) and (7)).
(5)
(6)
(7)
Davies et al. Page 11
Chem Commun (Camb). Author manuscript; available in PMC 2015 June 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
where μ0 is the permeability of vacuum (μ0 = 1.257 × 10−6 N A−2), γI is the gyromagnetic 
constant for protons (γI = 2.675 × 108 T−1 s−1), g is the electronic g-factor (g = 2), μB is the 
Bohr magneton (μB = 9.274 × 10−24 J T−1), S is the total electron spin of the material ion (S 
= 7/2 for Gd3+), F2 denotes the order parameter (vide infra) and T1e is the electron spin 
longitudinal relaxation time.97
As a result of the natively increased steric bulk of nanoparticles or macromolecules, 
tumbling of the appended molecular paramagnetic probe is, relatively, slowed down; the 
associated increase in overall rotational correlation time (τR) providing concurrent 
improvement of relaxivity.98 The length of τR for small molecular weight Gd3+-chelates is 
in the picosecond range (50–200 ps),99 1–3 orders smaller than τm and T1e, and so τC is 
dominated by τR.100 On the other hand, τR of their higher molecular weight counterparts is 
in the nanosecond range (0.5–50 ns), a timescale which is comparable or even longer than 
τm and T1e. Since eqn (4) predicts a higher relaxivity for a shorter τm value (τm << T1m) and 
T1m can already be more than one order of magnitude shorter in such systems (eqn (5) and 
(6)), the relaxivity of nanoparticulate contrast agents is characteristically limited by rather 
long τm and thus slow kex (kex = 1/τm).97
An important consideration in the design of macromolecular or nanoparticulate CAs with 
high relaxivity is the structure and flexibility of the linking moiety (it is not necessarily the 
case that the particle structural rigidity and rotational time are directly translated to 
appended complexes). Fast rotation around the Gd3+-complex linker compared to the motion 
of the nanoparticle can be a limiting factor in the relaxivity enhancement; if Gd3+-
complexes are covalently attached to the surface of the particle through a flexible linker, 
their local rotational motion (τRL) around the axis of the linker in solution is much faster 
than the global rotation of the nanoparticles (τRG) (Fig. 7). Using the Lipari–Szabo 
approach85,86 incorporated into the SBM equations, the relaxation parameters of 
nanoparticulate MRI probes can be obtained through fitting of experimental nuclear 
magnetic resonance dispersion (NMRD) profiles.101 The degree of spatial restriction of the 
motion, i.e., the extent to which τRL and τRG contribute to τR is described by the order 
parameter F2 (0 ≤ F2 ≥ 1). If τRL is negligible, as in a perfectly rigid system, F2 equals 1. In 
more conformationally flexible environments, F2 approaches 0, and internal motions are 
completely independent of global motion.96 These nanoscale effects are summarised in eqn 
(5), which is valid at B0 > 1.5 T if the global molecular reorientation is isotropic.3,97
This theoretical framework enables evaluation of the rigidity and the internal motions of the 
nanosized system, the influence of the length and flexibility of the contrast agent linker on 
the relaxation parameters, and the contributions emerging from both the appended molecular 
MRI probe and from the nanoparticle to the overall relaxation of the composite.102 The 
number of nanoparticulate-based MRI contrast agents has rapidly increased in recent years, 
due not only to their capacity to deliver a large number of paramagnetic ions per 
nanostructure, allowing improvements in relaxivity per unit dose compared to individual 
Gd3+-chelates, but especially, as noted, due to their ability to boost relaxivity by retarding 
the chelate tumbling rate.98
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The conjugation of Gd3+-chelates to block, graft, or micellar macromolecular carriers 
generates a class of CA whose relaxivity is dependent on the polymer rigidity.90,103 This, in 
turn, is chemically tuneable through the overall molecular weight,104 by the incorporation of 
monomers with high glass transition temperatures,105 by grafting of conjugated polymers 
possessing a more rigid backbone,106 enhancing the degree of cross-linking,107 lengthening 
and making side chains hydrophobic,102 or by increasing the number of internal hydrogen 
bonds (and hence reducing internal motion).90 Improved H2O exchange can be achieved by 
the incorporation of a hydrophilic shell layer that serves as a reservoir for water 
molecules.108 On the other hand, grafting polyethyleneglycol (PEG) chains onto 
hyperbranched polymers and dendrimers is known to slightly decrease relaxivity because of 
hindered water exchange.103,109 In dendrimers, relaxivity can be maximised with each 
increase in branching generation, through τR effects. This trend, however, is not exhaustive 
and has been found to decrease once the G9 generation is reached.13 Macromolecular 
formulations with an MRI sensitivity that is environmentally responsive in a simple manner 
can be achieved by selecting monomers with responsive functional groups,110 by gating the 
water accessibility,111 by conformational conversion between globular and extended 
form,107 through the incorporation of cleavable linkers,103 and by switching between 
hydrophobic interaction and electrostatic repulsion,112 amongst others.
Cone-like or truncated cone-like amphiphiles that self-aggregate into micelles or liposomes 
under specific conditions have also been utilised to improve CA relaxivity.13,97 Memsomes 
(Fig. 8) are a class of liposomes, where a paramagnetic complex can be attached to the 
hydrophilic heads of the lipid molecules in the bilayer, allowing easy access to solvent.13 In 
this case, the attachment of the paramagnetic complex to the membrane is not rigid (τRL << 
τRG), and so the size of the memsome itself has no effect on relaxivity.113 Instead, the latter 
is observed to be dependent on the rotational diffusion of the Gd3+-complex on the surface 
of the liposome,114 as well as on the length of the linker, tuning water accessibility to the 
lanthanide CA centre.115 On increasing the alkyl chain length from C10 to C18, τRG can 
increase from 500 to 2800 ps. However, the advantage of high τRG is reduced in all 
liposomal systems due to the high internal mobility of the Gd3+-complexes (short τRL and 
low F2), and slow kex.102 The latter is highly dependent on the phospholipid membrane’s 
water permeability in enosomes, which comprise a group of liposomes that encapsulate 
water-soluble Gd3+-chelates.97 Enhancement of the permeability concomitant with a 
shortened τio (i.e. water exchange time between internal, i, and external, o, parts of the 
liposome)116 can be achieved by increasing the temperature towards the phase transition 
temperature (TM) that causes phospholipids to undergo a gradual increase in fluidity. In this 
system, quenched r1 can only be recovered when the liposome composition allows for rapid 
water exchange between the interior and exterior of the enosomes (τio << T1i). 
Subsequently, relaxivity of the paramagnetic agent encapsulated within the liposome 
becomes similar to that in the solution. Higher concentrations of metal chelate encapsulated 
within the liposome and higher internal viscosity, further lengthens the rotational and 
diffusional correlation times, contributes to a slightly higher relaxivity compared to non-
encapsulated Gd3+-complex.91,116
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Another important class of highly tuneable nanoparticulate CAs consists of inorganic 
biocompatible Gd3+-chelate decorated mesoporous silica nanoparticles (MSNs) with 
uniform mesopore compartments and large silanol surface areas.94,117,118 The geometric 
confinement of the former increases τR of the paramagnetic complex and τD of water 
molecules (increasing the H2O–lanthanide interaction time) and, through this, 
relaxivity.85,119 The tuneable surface chemistry can be further exploited to improve the 
accessibility of water and increase the water-exchange rate, kex. For example, a threefold 
faster kex was reported after acetylation of surface amine groups otherwise used for 
conjugation to Gd3+-chelates.120
It is clear, then, that nanostructured and macromolecular materials can provide improved 
MRI signal contrast due to their behaviour in suspension. Such materials can be further 
engineered to offer stimuli responsive contrast in a predictable and useful manner. Their 
characteristics can be tuned through design and synthesis in terms of q,121 τRL,122 τRG,89, 
τio123 or τm,114 and have the capability to additionally provide specificity to a site of 
interest, high in vivo mobility, and multimodality as well as multifunctionality. As such, they 
represent an increasingly important class of MRI contrast agent.
3.1 pH-responsive particulate contrast agents
Nanoparticulate MRI probes can be designed to exhibit significant contrast response to 
physiological or pathological pH change in the region of interest.124 Most typically, this is 
through the incorporation of pH-responsive Gd3+-chelates,125 acid labile linkers such as 
ketals126 or pH-responsive groups into a nanoparticle scaffold,127 whose pH-responsiveness 
triggers a global response across the particle, such as a change in hydration state (leading to 
swelling/collapse), propensity to degrade/dissolve, hydrophilic/hydrophobic change, 
hydrodynamic diameter, conformational change (globular/linear), micellisation, or change in 
water permeability. These changes can result in marked changes in F2,112 q,128 or τm,68 and 
thus T1 contrast.
Such structural changes are, of course, markedly more useful if the responsive functional 
groups possess pKa values around physiological pHs (frequently employed groups which 
affect the hydration state q as a result of a response to a stimuli, include arylsulfonamide,16 
imidazole,124 nitrophenol,129 and phosphonate125). Aime and co-workers have, for example, 
reported an adamantane derivative of a sulfonamide based Gd3+-chelate that was non-
covalently hosted by a macromolecular carrier consisting of 8–10 poly-β-cyclodextrin units. 
With a pKa of 6.7, the sulfonamide nitrogen deprotonates at basic pH and ligates to the metal 
centre, generating an “MRI silent” q = 0 state (a reversible change to q = 2 at acidic pH, 
‘turning on’ relaxivity contrast). An additional integration into the same cyclodextrin 
scaffold of an adamantane functionalised 19F-containing reporter can additionally engender 
ratiometric 1H/19F mapping of pH.128
On the other hand, anionic, pH-sensitive polymers, such as those based on polymethacrylic 
acid (PMMA), can accept or release protons (Fig. 9), resulting in swelling/contraction that 
modifies τR.112 At pH 7, a Gd3+–DO3A loaded spherical copolymer consisting of PMMA 
cross-linked by N,N′-methylenebisacrylamide becomes swollen due to electrostatic 
repulsion between the carboxy groups. At pH 4 carboxy group protonation induces the 
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formation of a compact globule conformation of restricted molecular motion and r1 
increases from 13.6 mM−1 s−1 to 28.0 mM−1 s−1.107
The remarkably higher τR of a generation-5 poly(amidoamine) (G5-PAMAM) dendrimer 
loaded with Gd3+–EPTPA in an acidic environment was studied in detail by Merbach and 
co-workers using the Lipari–Szabo approach to fit NMRD profiles. Under acidic conditions, 
repulsions between positively charged atoms associated with protonation of tertiary amines 
were increased, leading to an extended dendritic structure of slower global rotation (longer 
τR due to increased τRG = 4.04 ns) and increased hydrogen bond governed rigidity (F2 = 
0.43). The increases in τRG and F2 above those noted at basic pH (τRG = 2.95 ns, F2 = 0.36), 
generated relaxivity increases from 13.7 to 23.9 mM−1 s−1 at low pH.90
The opposite effect of pH on τR was reported for a macromolecular probe comprising 114 
ornithine residues, 30 of which were linked to aminoethyl-functionalised Gd3+–DO3A 
through a squaric acid moiety. At acidic pH, cationic terminal amine side chains were highly 
hydrated and repelling, generating a highly flexible structure of low τR and r1. At basic pH, 
deprotonation of the amine groups led to formation of a rigid α-helix structure, with an 
associated increase in r1 to 32 mM−1 s−1.131 This behaviour was consistent with increasing 
τR with pH as determined by NMRD. Above pH 7, the R2/R1 ratio was independent of the 
local concentration of the paramagnetic agent allowing ratiometric imaging.132
Both τm and τR contributed to responsiveness when 96 Gd3+-chelate moieties, each with 
four pH-sensitive phosphonate pendant arms that form hydrogen-bonds with bulk water 
(phosphonate triggered protic exchange in the second-hydration sphere133 is described in 
Section 2.3), were covalently coupled to a G5-PAMAM dendrimer by the group of Sherry. 
At pH 9, r1 (10.8 mM−1 s−1) was reportedly limited by slow water exchange. As the pH fell 
below 8.5, the phosphonates were consecutively protonated, and their effectiveness at 
catalysing proton exchange at Gd3+-coordinated H2O with bulk H2O increased. The 
combined effects of faster inner-sphere water exchange, longer τm of the second sphere due 
to either a larger or more ordered second coordination shell (via protonated phosphonates), 
and longer τR as a result of protonation of amines within the dendrimer, (turning on 
hydrogen bond mediated rigidification),90 increase r1 to 24.0 mM−1 s−1 at pH 6. However, 
the ultimate relaxivity here was limited by relatively slow water exchange in the inner-
sphere (in the microsecond range) and by relatively fast protic exchange in the second-
sphere (in the nanosecond range).134
τm and τR have also been pH tuned through the loading of an amphiphilic Gd3+–DO3A 
derivative bearing a sulfonamide moiety into large unilamellar vesicles (LUV). Subsequent 
relaxivity decreases at high pH were ascribed not only to changes in inner-sphere hydration 
of the Gd3+-chelate (from q = 2 to q = 0), but also to its changed intraliposomal distribution 
and water exchange across the vesicle’s membrane. In an acidic environment, protonation of 
the sulfonamide moiety with concomitant removal of the arm from the coordination cage of 
the Gd3+-ion caused its incorporation deeper into the liposomal membrane. As a result, the 
increased number of Gd3+-complexes intercalated into the membrane led to a higher τR with 
respect to the free complex, an elongated τm, an increased membrane permeability to water 
and consequently an enhanced relaxation rate R1. In a rather unusual step, the authors finally 
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report that, in mapping the dependence of the ratio of the 1H R1 relaxation rates at two 
different magnetic fields (40 MHz and 8.5 MHz) on pH (Fig. 10) ratiometric pH MR 
imaging can be achieved (image contrast independent of CA concentration).135
There are, then, several different approaches which can be employed in the generation of 
high r1 CAs with pH sensitive contrast. The most common approaches utilise either pH 
dependent swelling, causing variations in τR, or pH dependent metal hydration/water 
exchange rate. In most cases, relatively modest (~2-fold) changes in relaxivity have been 
achieved to date. The potential within this field, however, is vast, with a range of disease 
states triggering notable variation in local pH profile. This is likely to be an area of active 
publishing in the coming years.
3.2 Redox-responsive particulate contrast agents
In comparison to pH, there are relatively few examples of particulate-based T1 MRI probes 
for which contrast is tuned through a redox event. To date, examples are primarily based on 
changes in rotational correlation time. For example, the redox-responsive relaxivity change 
of a nanoparticulate MRI probe based on a thiol/disulfide redox couple is caused by 
variation in molecular dynamics (τR) as a result of degradation. Nanocapsules based on 
several β-CD units linked by disulfide bridges incorporated Gd3+-chelates that were able to 
interact with β-CD via hydrophobic pendant aromatic residues. The incorporated Gd3+-
chelates exhibited high relaxivity (15.2 mM−1 s−1 at 70 MHz) due to restricted mobility and 
good water permeability through the β-CD shell. The addition of a reducing agent caused the 
nanocapsules to disassemble, releasing the β-CD monomers and Gd3+-complexes. As a 
result, τR was shortened and relaxivity decreased to 8.2 mM−1 s−1.136
In comparable work but with converse observations, Liang and others obtained an enhanced 
relaxivity through elongated τR as a consequence of self-assembly of gadolinium doped 
nanoparticles triggered by enzymatic and reductive cleavage.137 After entry into cancer 
cells, the disulfide bond of an MRI contrast agent (r1 = 6.0 mM−1 s−1) consisting of Gd3+–
DOTA, 2-cyanobenzothiazole and a peptide sequence containing an S–S bond, was reduced 
by glutathione and the peptide sequence cleaved by furin, a trans-Golgi protease 
overexpressed in tumours. The so-generated intermediate Gd3+-complex condensed into an 
amphiphilic dimer with increased relaxivity (13.2 mM−1 s−1), self-assembling via π–π 
stacking into gadolinium containing nanoparticles, with τR once again being responsible for 
contrast modulation.138
These examples demonstrate that effective relaxation responses can be observed using a 
redox stimulus, although reductions in relaxivity resulting from dissolution are less useful 
from a potential toxicity perspective, increases due to lengthened τR can provide >100% 
contrast signal enhancement.
3.3 Thermo-responsive particulate contrast agents
Temperature sensitive nanoparticulate MRI probes can potentially be used for both 
measuring temperature distribution in the human body, and thermometry, the latter largely 
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based on local hyperthermia for either chemodosimetry or controllably killing cancer 
cells.123,139,140
In terms of CA relaxivity, work to date has focused on either temperature induced release of 
Gd3+-chelates from a liposomal core140 or by a change in water access to particle 
internalised Gd3+-complexes.141,142 In both cases all prior work has been based on the 
transition of the liposomal phospholipid bilayer from a highly ordered gel-like phase that 
serves as a diffusion barrier to a fluid-like disordered state with increased membrane 
permeability (at T > TM).123
Grüll and others have, for example, investigated liposomes consisting of several different 
lipids including a thermoresponsive 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, 
TM = 41.5 °C140), and a lysolipid 1-palmitoyl-sn-glycero-3-phosphocholine (MPPC). T1 
measurements at T < TM imply that encapsulated Gd3+-complexes remain inside the aqueous 
lumen of the liposome so that relaxivity is limited by the water diffusion across the bilayer. 
This increases with increasing temperature, such that there is a sharp reduction in T1 (from 
1828 ms to 394 ms) above the TM, upon incubation of the liposomes at 45 °C for 30 min.143
In vivo studies were performed by Li et al., who developed a DPPC-based thermo-sensitive 
liposomal formulation with encapsulated Gd3+–DTPA and doxorubicin. Chelate release was 
triggered by local hyperthermia and quantified by MRI. T1 relaxation of a tumour in a 
BALB/c mouse treated by such liposomes was 2878 ms. After hyperthermic treatment in a 
hot bath at 43 °C, T1 was accelerated to 1509 ms in the rim (i.e. 1–2 mm band around 
tumour periphery) and to 2482 ms in the core of the tumour due to Gd3+–DTPA release.144
A two-point thermometry system with an “off–on” and “on–off” transition using lipid 
nanoparticles containing P(NIPAM)-co-P(AM) crosslinked with a Gd3+-chelate bi-linker 
was developed by Wu and others.145 Poly(N-isopropylacrylamide) P(NIPAM) exhibits a 
unique temperature sensitivity, undergoing a reversible phase transition at 32 °C, expelling 
water and forming a contracted hydrophobic globule of low associated relaxivity.146 The 
critical temperature of this transition could be raised with increasing amounts of 
copolymerised temperature insensitive monomer acrylamide (AM). At temperatures above 
the critical point the hydrophilic hydrogel containing the Gd3+-chelate crosslinker was 
exposed to water, increasing T1 signal.145
These investigations into the use of temperature activatable contrast agents exploiting 
tuneable interactions between bulk water and paramagnetic chelate have been successfully 
translated to in vivo studies and shown great promise,144 particularly considering the 
demonstrable biocompatibility of the materials involved. Further analyses will undoubtedly 
present systems of greater control, tuneability and temperature definition.
3.4 Bio-responsive particulate contrast agents
Smart MRI nanoparticulate probes endeavour to sense molecular events, such as enzymatic 
activities and gene expression patterns at the level of the entire organism.147 A number of 
attempts have been made to generate macromolecular contrast agents that respond 
significantly to the presence of a biomolecule of interest based on the so-called receptor-
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induced magnetisation-enhancement (RIME) effect.148 In many cases this has been achieved 
through a modulation of τR. Biotinylated DNA aptamers 3′ conjugated to Gd3+–DOTA 
have, for example, been observed to switch the terminal r1 relaxivity by ~40% in the 
presence/absence of adenosine. This sensing occurs through binding induced changes in 
DNA hybridisation with its associated change in steric bulk.149 Similarly, T1 contrast of a 
G5-PAMAM dendrimer conjugated to folic acid and Gd3+-complex can be enhanced upon 
binding to a folate receptor due to resulting slower tumbling rates.150 Similarly, the 
relaxivity of a gadolinium metallopeptide consisting of a DNA-binding transcription factor 
and a Ca2+-binding moiety increased r1 by 100% to 42.4 mM−1 s−1 at 60 MHz upon binding 
to DNA, due to an increased τR effect.151 A τR dependent relaxometric procedure was also 
developed by Aime and others, who exploited a ratiometric couple based on Gd3+–DOTA 
covalently linked to a peptide sequence and a lipophilic tail that was incorporated into a 
liposome (large R2/R1). As the matrix metalloproteinase-2 cleaved the sequence between 
serine and leucine, the gadolinium complex was released from the liposomal membrane, 
and, due to increased τR, R2/R1 was reduced by ~46% at 300 MHz independent of the total 
concentration of gadolinium.152
In addition, a Gd3+ complex itself can be responsive to direct ligation to a biomolecule, 
whereby the number of inner sphere bound water molecules q changes upon binding. This 
conceptually and chemically simple mechanism has, for example, been demonstrated with 
an octahedral nanocage consisting of four rigid tridentate ligands coordinating six 
gadolinium atoms that showed a r1 of 388.5 mM−1 s−1, at 400 MHz. Addition of 
glucosamine triggered a decrease in r1 to 62.1 mM−1 s−1 due to substitution of coordinated 
water molecules and decreased q (selectivity over glucose was notably observed).110
Davis and co-workers have explored the first inorganic nanoparticle-based contrast system 
triggered by protein–protein recognition based on tuned water access and τm (Fig. 11).111 
They specifically reported the reversible contrast switching of Gd3+-chelate doped MSNs (r1 
= 15.1 ± 0.57 mM−1 s−1 at 300 MHz) by tuning the water access to internally biased 
paramagnetic centres (and thus kex) using a surface immobilised protein of sufficient steric 
bulk (in the protein gated state r1 = 5.8 ± 0.22 mM−1 s−1). In the presence of a partner 
biomolecule (in this case a biotinylated protein), this steric cap was observed to be competed 
off, and both water access and high relaxivity were subsequently restored. This proof of 
principal serves to illustrate the significant potential of nanoparticle-based functional MR 
imaging in reporting on specific biorecognition processes.
The wide variety of potential bio-responsive triggers available which are associated with 
various disease and tumour states should stimulate further investigations into nanoparticle 
scaffolds, wherein both inherently high signal contrast and potentially dramatic contrast 
switching are possible.
4. Conclusions and future outlooks
There exist a plethora of MRI CAs which are capable of displaying strong positive or 
negative signals in vitro and in vivo. The prospect of CAs which can detect and respond to 
specific stimuli is an exciting one, with huge potential for non-invasive disease diagnosis 
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and, more generally, the (potentially whole body) “mapping” of local biochemistry. This 
article has focused on T1 paramagnetic centre-based contrast agents, and described some of 
the mechanisms which can be exploited to facilitate change in MRI contrast signal in 
response to a specific environmental trigger (see Table 1). Molecular, macromolecular and 
particulate-based contrast agents can, specifically, be engineered such that variations in 
hydration number (q), rotational correlation (τR) or water exchange (τm) follow specific 
chemical or physical interactions with their environment.
In general, macromolecular and particle-based CAs provide higher relaxivity values than 
molecular agents alone, due in part to significant lengthening of the paramagnet rotational 
correlation times through its association with a rigid, bulky, species. The degree of relaxivity 
modulation observed, however, is, thus far, similar for both molecular and nanoparticulate 
agents (see Table 1). As protocols for the synthesis of homogeneous and well-characterised 
particles become widely used, this area is likely to develop markedly over the next few 
years. Tactics to facilitate response are likely to involve designed switching of τR and τm, as 
well as gating water access to encapsulated paramagnetic centres. The possibility of utilising 
additional (native or added) multimodal characteristics (nuclear or otherwise), high local 
concentrations and targeting would make these agents exceedingly powerful from a 
diagnostic perspective.
To date, it is clear that the chemical complexities of an in vivo environment often prove 
detrimental in keeping image contrast switches both substantial and selective. The 
development of improved particle characterisation methodologies together with chemistries 
that introduce other magnetic nuclei, chemically exchangeable groups, or hyperpolarized 
centres, will, however, almost certainly underpin beneficial developments.153-158
Few areas of research have exploded quite as dramatically as the development of both 
molecular and nanoparticle based image contrast and therapeutic delivery systems during the 
past decade. Applying the chemists’ toolkit and additionally integrating a non-invasive 
means of diagnosing and monitoring response to a treatment regime would, quite simply, 
herald a new age in clinical healthcare.
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Fig. 1. 
Schematic representation of inner, second and outer sphere water interaction with a typical 
T1 contrast agent, a Gd–DOTA chelate.
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Fig. 2. 
Schematic representation of Egad MRI contrast agent; galactopyranose groups (red) are 
removed via β-galactosidase cleavage, resulting in an irreversible transition from a weak to a 
strong relaxivity state, reproduced with permission from ref. 28. Copyright 1997 Wiley-
VCH Verlag GmbH & Co. KGaA.
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Fig. 3. 
Illustration of the generic association between a Gd3+ chelate (brown sphere) and a protein 
target (purple) resulting in lengthened τR and improved MRI contrast.
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Fig. 4. 
A proposed mechanism of MRI relaxivity modulation based on hydration (q) alterations due 
to pendant acetate coordination in the presence of Zn2+ ions, adapted with permission from 
ref. 45. Copyright 2008 American Chemical Society.
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Fig. 5. 
Representation of MRI contrast agent species with Cu+/2+ selectivity, where L is a ligand, 
such as a thioether-based donor, n = 1, 2; adapted with permission from ref. 50. Copyright 
2009 American Chemical Society.
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Fig. 6. 
Redox-sensitive structural isomerisation of spiropyran–merocyaninetethered GdDOTA, 
adapted with permission from ref. 74. Copyright 2009 Wiley-VCH Verlag GmbH & Co. 
KGaA.
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Fig. 7. 
The relaxivity of a nanoparticulate MRI probe (blue sphere) with conjugated Gd3+-
complexes (brown spheres) is determined by the local rotational time of the complex around 
the linker (τRL), the global rotational motion (τRG), and the coordinated water exchange rate 
(kex = 1/τm). Adapted with permission from ref. 97. Copyright 2012 Wiley-VCH Verlag 
GmbH & Co. KGaA.
Davies et al. Page 32
Chem Commun (Camb). Author manuscript; available in PMC 2015 June 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 8. 
Schematic representation of local and global mobility processes relevant to Gd3+-chelates 
(brown spheres) in (a) cross-linked polymeric nanoparticles, (b) dendrites, (c) enosomes, 
and (d) memsomes with τRG and τRL representing global and local rotational correlation 
times, respectively. Paramagnetic chelates are covalently bound in (a) and (b); for the 
paramagnetic chelates encapsulated (in (c) and (d)) in the membrane or aqueous phase of a 
liposome, τio denotes water exchange rate between the interior and exterior and τRi the 
rotational correlation time of the internalised complex.
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Fig. 9. 
The carboxylic groups of anionic polymeric nanoparticulates are progressively deionised 
when exposed to an acidic environment resulting in polymer shrinking, restricted side chain 
mobility, and significantly increasing relaxivity.107 The blue net represents the polymer and 
brown spheres the Gd3+-chelate groups covalently conjugated to polymer side chains. 
Picture adapted with permission from ref. 130.
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Fig. 10. 
NMRD profile showing the pH tuned1H longitudinal relaxivity of LUV loaded with a Gd3+–
DO3A derivative (1 mM [Gd]) as a function of applied magnetic field. The colour scale bar 
in the arrow denotes the signal intensities of T1-weighted images, and the two red bars 
represent 1H relaxivities at two different magnetic fields (8.5 MHz and 40 MHz). Adapted 
with permission from ref. 135. Copyright 2012 American Chemical Society.
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Fig. 11. 
Schematic summary of the protein gating of MSNs. Externally biotinylated Gd–DOTA 
MSNs enjoy good water accessibility and a high relaxivity that can be reversibly capped by 
the steric bulk of bound streptavidin. In the presence of low μM of biotinylated BSA, the 
gating protein is competed off the particle surface and relaxivity recovers. Adapted from ref. 
111 with permission from The Royal Society of Chemistry.
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Table 1
Summary of relaxivity responses to various environmental stimuli of molecular, macromolecular, polymeric 
and particulate MRI CAs
Responsive MRI probe Stimulus Mechanistic change
r1 switch 
[mM−1 s−1] Percentage change Ref.
Molecular MRI CAs
4,7,10-Tri(acetic acid)-1-(2-β-galactopyranosylethoxy)-
1,4,7,10-tetraazacyclododecane gadolinium (EGad)
β-Galactosidase q Not reported 20% decrease 28
(l-(2-(β-Glalactopyranosyloxy)propyl)
-4,5,10-tris(carboxymethyl-1,4,7,10-tetra-
azacyclododecane))gadolinium (EGadMe)
β-Galactosidase q 0.90–2.72 
s−1 
a
 at 500 
MHz
200% increase 29
Gd–DO3A bearing a pendant β-glucuronic acid
moiety connected by a self-immolative linker
β-Glucuronidase q 4.75–3.90 at 
60 MHz
20% decrease 30
Gd–DO3A appended with acetoxymethyl esters Porcine liver
esterase
q 5.7–10.8 at 
20 MHz
89% increase 32
Bis-5-hydroxytryptamide-diethylenetriamine-pentatacetate
gadolinium (MPO–Gd)
Myeloperoxidase
(MPO)
τ R Not reported Not reported 27
Gd–DTPA with phosphonate side chain (MS-325) Human serum
albumin (HSA)
τ R 5.6–50.8 at 
20 MHz
800% increase at 
20 MHz
33
5.0–25.0 at 
64 MHz
400% increase at 
64 MHz
Gd–DTPA appended with lysine residues Thrombin-activa-
table fibrinolysis
inhibitor (TAFI)
τ R 12.5–25.2 at 
20 MHz
100% increase 34
Gd–DOTA with pendant diphenylphosphinamide groups Human serum
albumin (HSA)
τ R 7.3–16.0 at 
20 MHz
119% increase 36
Gd–DO3A–glutamate Glutamic acid
decarboxylase (GAD)
q, τR 8.0–11.5 at 
20 MHz
44% increase 31
Peptide-labelled GdDO3A (Gd3+–G80BP) Ga180 protein τ R 8.3–44.8 at 
20 MHz
440% increase 35
Gd–DTPA bisamide Zn2+ q 6.06–3.98 at 
300 MHz
34% decrease 39
Gd–DTPA bisamide Zn2+ q 4.8–3.5 at 
300 MHz
27% decrease 40
Gd–DTPA-appended β-diketone (KMR–Mg) Mg2+ (also Ca2+) q 4.98–3.95 at 
20 MHz
21% decrease 41
Gd–DOTA appended with N,N-bis(2-pyridyl-methyl) 
ethylene diamine (bisBPEN) diamide
Zn2+, Cu2+ k ex 5.0–6.0 at 
23 MHz
20% increase 42
Gd–DOTA appended with two bis-(3-pyrazolyl) units Zn2+, Cu2+ k ex 4.2–6.9 at 
23 MHz
64% increase 43
Gd–diaminoacetate with 3 methylenes (Gd–daa3) Zn2+ q 2.3–5.1 at 
60 MHz
121% increase 44, 45
Gd[l,2-bis[{[({l-[l,4,7-tris(carboxymethyl)-1,4,7,10-tetra-
azacyclododecane-10-yl]eth-2-yl}amino)carbonyl]methyl}-
(carboxymethyl)amino]ethane]
Ca2+ q 5.4–7.1 at 
500 MHz
32% increase 46
Ethylene glycol tetraacetic acid (EGTA) linked
to 2 Gd–DO3A chelates
Ca2+ q 3.44–6.29 at 
500 MHz
83% increase 47
DOPTA–Gd Ca2+ q 3.26–5.76 at 
500 MHz
80% increase 48
Gd–DO3A chelate with pyro-EGTA moiety Ca2+, Zn2+ q 3.8–6.6 at 
60 MHz
73% increase 55
Gd–DO3A with a pendant iminodiacetate Cu2+ q 3.76–5.29 at 
400 MHz
41% increase 49
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Responsive MRI probe Stimulus Mechanistic change
r1 switch 
[mM−1 s−1] Percentage change Ref.
Gd–DO3A with tethered thioether groups Cu2+ q 1.5–6.9 at 
20 MHz
360% increase 50
Octaarginine-conjugated Gd–DO3A with tethered thioether 
groups
Cu+ q 3.9–12.5 at 
60 MHz
220% increase 52
Gd–DO3A with appended 8-amidequinoline (Gd-
QDOTAMA)
Cu2+ q 4.27–7.29 at 
400 MHz
71% increase 53
Tryptophan-appended Gd–TTDA [Gd(Try-TTDA)(H2O)]2− Cu2+ q 4.22–7.42 at 
20 MHz
76% increase 54
Di-metallic-DO3A with piperazine bridge Hg2+ q 8.3–10.3 at 
30 MHz
24% increase 51
GdDOTA–diBPEN Zn2+ τ R 5.0–17.5 at 
23 MHz
250% increase 57
Gd(phen)HDO3A chelate Fe2+ τ R 3.7–12.2 at 
20 MHz
230% increase 11
[Gd2bpy(DTTA)2(H2O)4]2− Fe2+ τ R 12.44–20.17 
at 20 MHz
62% increase 59
Terpyridine–Gd3+ chelate pH q 12.8–2.0 at 
20 MHz
84% 66
[Gd(DOTA tetrakis(methylamide))]3+ pH τ m 2.5–5.7 at 
20 MHz
128% 22, 23
Dinitrospiropyran–GdDO3A NADH q 2.51–1.86 at 
60 MHz
26% decrease 74, 75
Spiropyran–GdDO3A NADH q 5.58–8.60 at 
60 MHz
54% increase 74
Spiropyran–GdDO3A Light q 3.72–2.93 at 
60 MHz
21% decrease 75
Macromolecular, polymeric and particulate MRI CAs
G5-PAMAM dendrimer with Gd-complexes
bearing phosphonate pendant arms
pH τR, τm 10.8–24.0 at 
20 MHz
122% 134
Large unilamellar vesicles (POPC/DPPC)
loaded with the an amphiphilic GdDO3A derivative
pH τR, τm 4.5–13.5 at 
43 MHz
200% 135
Sulfonamide arm containing Gd-chelate
hosted by poly-β-cyclodextrin
pH q 8–16 at 43 
MHz
100% 128
Diacylphosphatidylethanolamine/
dipalmitoylglycerosuccinate based enosome
loaded with a GdDTPA-derivative
pH τ io 2.3–0.7 at 
20 MHz
228% 159
Poly-L-ornithine pH τR, τm 23.0–32.0 at 
20 MHz
39% 131
Methacrylic acid based polymer cross-linked
by N,N′-methylenebisacrylamide
pH Swelling (τR) Non-cross-
linked 
polymer: 
6.7–12.1 
Cross-
linked 
polymer: 
13.6–28.0 at 
20 MHz
106% 107
n-Octylamine modified poly(SM-EVE)
polymer loaded with aminoethyl-modified GdDO3A
pH Electrostatic
repulsion (high pH),
hydrophobic
interaction (low pH) 
(τR)
8.0–9.0 at 
20 MHz
12% 112
Avidin conjugated to GdDOTA derivative
with a phosphonate pendant arm
pH τR, q 10.4–12.6 at 
128 MHz
21% 160
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Responsive MRI probe Stimulus Mechanistic change
r1 switch 
[mM−1 s−1] Percentage change Ref.
Ketal-based polymer with a GdDTPA derivative pH Polymer
degradation (τR)
8.2–3.8 at 
64 MHz
115% 126
Gadonanotubes pH Gd3+ loss 40.0–133.0 
at 64 MHz
233% 86
Gadofullerenes pH Aggregation (τR) 10.4–38.5 at 
30–60 MHz
270% 161
Manganese oxide nanoparticles pH Release of
Mn2+ ions
8.8–27.7 at 
64 MHz
215% 162
Manganese oxide
functionalised mesoporous silica nanoparticle
pH Dissolution 0.8–8.8 at 
128 MHz
1015% 163
GdDOTA doped mesoporous silica nanoparticles capped by 
streptavidin
Biotinylated BSA τ m 5.8–12.7 at 
300 MHz
219% increase 111
Hexanuclear gadolinium organic octahedron Glucosamine kex, q 388.5–62.1 
at 400 MHz
526% decrease 110
Manganese loaded apoferritin Melanin Reduction,
dissolution (τR)
0.3–6.0 at 
300 MHz
1900% increase 164
DNA aptamer conjugated to streptavidin
and GdDOTA
Adenosine Release of Gd-DNA
strand (τR)
12.2–9.2 at 
60 MHz
33% decrease 149
Liposome with incorporated amphiphilic
GdDOTA covalently linked to a peptide sequence
Metalloproteinase-2 τ R 8.9–7.5 at 
60 MHz
16% decrease 152
GdDOTA covalently coupled to a chemically modified 
peptide
sequence bearing a cyano and 1,2-aminothiol group
Furin Reduction,
self-assembly into
nanoparticles (τR)
6.0–13.2 at 
64 MHz
220% increase 137
Perthiolated β-cyclodextrin-based nanocapsules Reductive/hypoxic
environment
Reduction,
degradation (τR)
15.2–8.2 at 
70 MHz
46% decrease 136
P(NIPAM)-co-P(AM) hydrogel nanoparticles cross-linked 
by a
GdDTPA-derivative and loaded into solid lipid 
nanoparticles
Temperature kex, τio, τR 12.4–8.6 at 
300 MHz
44% decrease 145
POEGMA-b-P(NIPAM-co-NBA-co-Gd) diblock copolymer Temperature k ex 6.5–12.1 at 
300 MHz
86% increase 165
Liposomes loaded with Gd-complexes Temperature τ io 1828–394 
ms
b
 at 300 
MHz
364% decrease 143
a
Relaxation rate provided in s−1.
b
Relaxation time provided in ms.
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